INBRAIN’s “Rice‑sized” Graphene BCI Chip Marks New Phase in Merck Collaboration

Why It Matters

The chip could accelerate BCI‑based therapies for speech impairments, creating a commercial market for neuroelectronic devices and signaling major pharma commitment to graphene bioelectronics.

Key Takeaways

• Rice-sized graphene BCI chip enables bidirectional brain communication
• Merck moves from R&D to product commercialization with INBRAIN
• AI algorithms adjust stimulation parameters in real time
• Speech-decoding trial targets communication aid for neurological patients
• Series B funding and imec partnership scale graphene manufacturing

Pulse Analysis

Graphene’s unique electrical conductivity and flexibility have made it a promising material for next‑generation brain‑computer interfaces. Compared with traditional silicon electrodes, graphene arrays can capture higher‑frequency neural activity while remaining ultra‑thin, reducing tissue irritation. This material advantage underpins INBRAIN’s ability to shrink its BCI platform to a rice‑sized chip, a milestone that could lower surgical risk and broaden adoption across neuromodulation therapies.

The partnership between INBRAIN and Merck, launched in 2021, is now transitioning from exploratory research to market‑ready product development. Merck’s involvement brings deep regulatory expertise and capital, accelerating the path to a speech‑decoding clinical trial that leverages the chip’s closed‑loop capabilities. Real‑time AI algorithms interpret gamma‑band signals linked to language, then modulate stimulation parameters, offering a potential communication bridge for patients with locked‑in syndrome or ALS. This integration of advanced materials, AI, and pharma resources exemplifies a new collaborative model for neurotechnology commercialization.

Commercial implications are significant. With Series B funding and a manufacturing partnership with imec, INBRAIN is positioned to produce graphene neural interfaces at scale, addressing a growing demand for minimally invasive neurotherapeutics. Successful trial outcomes could unlock reimbursement pathways and attract further investment from pharmaceutical giants seeking to diversify into digital therapeutics. As competitors race to develop implantable BCIs, INBRAIN’s compact, bidirectional chip may set a benchmark for performance and manufacturability, shaping the future landscape of brain‑machine communication.